Robert Lin, MD, PhD, is a physician and researcher who has conducted dozens of multinational clinical trials and is experienced in genomics and proteomics. His extensive background in clinical medicine and basic research enables him to delve into the fundamentals of new innovations and provide thorough assessments of their clinical applications. Dr. Lin has evaluated hundreds of biotech and healthcare investments and has been involved in dozens of multi-million-dollar biotech deals. He serves as a trusted advisor on multiple committees in the Asia-Pacific region.

Dr. Lin has served as the vice director of the Internal Medicine Department at a tertiary medical center in Taiwan and as a member of the censorship committee of the AAHRPP-certified Institutional Review Board. He conducted post-doctoral research at Lawrence Berkeley Laboratory in the USA.